EMJ GOLD

Gavi has committed $50m to efforts towards vaccine approval for the Ebola virus outbreak in the Democratic Republic of the Congo and Uganda, caused by the Bundibugyo virus.

Despite the positive efficacy data, investor attention has turned to survodutide’s tolerability profile.

The guidance allows sponsors to build on data generated from previous R&D programmes.

The targeted therapy will be available for patients with epithelial ovarian, peritoneal, or fallopian tube cancers.

From a potential breakthrough in pancreatic cancer to fresh Ebola concerns and more FDA leadership turmoil, discover the most-read stories.

A phase 2a study has revealed encouraging early evidence for cancer metastasis prevention, with fewer metastatic recurrences and no metastasis-related deaths in treated patients.

There is no licensed vaccine for the current Bundibugyo strain, with three vaccine makers hoping they hold the key.

Ethiopia, Ghana, Honduras, Nigeria, Senegal and Zambia, Belgium and Luxembourg have scaled-up commitments to women’s reproductive healthcare.